Compare CUE & TRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUE | TRAD |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 148.0M |
| IPO Year | 2017 | 2025 |
| Metric | CUE | TRAD |
|---|---|---|
| Price | $4.59 | $10.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $68.67 | N/A |
| AVG Volume (30 Days) | ★ 552.6K | 60.6K |
| Earning Date | 11-16-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $9.93 |
| 52 Week High | $45.50 | $10.13 |
| Indicator | CUE | TRAD |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 55.31 |
| Support Level | $0.22 | $9.99 |
| Resistance Level | $33.95 | N/A |
| Average True Range (ATR) | 2.75 | 0.02 |
| MACD | -1.47 | -0.00 |
| Stochastic Oscillator | 8.18 | 73.17 |
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
APEX Tech Acquisition Inc is a blank check company.